- Merck Serono partners with Ono to treat cancer and MS
Ono Pharmaceuticals and Merck Serono entered two agreements covering the former's ONO-4641, a midstage oral compound for multiple sclerosis, and the latter's Stimuvax, a late-stage immunotherapy for cancer. The first deal gives Merck Serono worldwide rights excluding Taiwan, South Korea and Japan to ONO-4641 for $18.75 million upfront plus milestone fees. For the second contract, Ono will pay Merck Serono about $6.7 million upfront for Japanese co-development and co-commercialization rights to Stimuvax. Genetic Engineering & Biotechnology News (10/4)        | The Diabetes Report Series offers unprecedented access to current sentiment among patients with diabetes and the physicians who treat them. Thoughts, feelings, attitudes and intent are all revealed through the behavioral data collected from across the internet. Click here to review our FREE executive summaries on pivotal topics in Diabetes care. | - Experts: Stem cell therapies can help reduce health care costs
Experts at the World Stem Cell Summit in Pasadena, Calif., say stem cell therapies for stroke, heart attack and other diseases affecting baby boomers could help the U.S. health care system save money. Stem cells may also be used to treat those with pulmonary fibrosis and congenital kidney disease and premature babies with chronic lung disease , said Dr. David Wharburton of the University of Southern California's Keck School of Medicine Children's Hospital. KPCC-FM (Los Angeles) (10/4)  | Kickstart your business’ marketing with FedEx Office! Save big on posters, postcards and brochures, with up to 40% off on select print products. Go to FedEx Office to take advantage of the Look Good On Paper Print Sale to get discounts on all your business printing needs. |
  | Company & Financial News |  |  | | - Stada CEO: Company would consider merger with a biotech company
Since Germany-based Stada Arzneimittel is already established in the field of generic drug manufacturing, the company would consider merging with a biotech company or a maker of brand name drugs, said CEO Hartmut Retzlaff. Retzlaff said Stada is not in talks with any potential merger partners, and the company has yet to determine how well it collaborates with Hungary-based Gedeon Richter before it can consider forging a merger deal. Stada partnered with Gedeon to develop generic copies of Roche Holding's cancer drugs, Rituxan and Herceptin. Bloomberg (10/3) - Lilly, Boehringer will promote each other's diabetes drugs in India
The Indian subsidiaries of Boehringer Ingelheim and Eli Lilly and Co. agreed to co-promote each other's treatments for diabetes. The partnership includes Lilly's insulin Humalog and Boehringer's Linagliptin, an oral medicine not yet approved in India. "Such alliances are ways of balancing out in the huge India market," said a health care industry consultant. "They want to compete with one another. But at the same time use each other's strengths to stabilize themselves here." DNA (India) (10/4)  | The Plum Card®
The Everything, Everywhere Trade Terms CardSM from American Express OPEN
• Pay in full within ten days, get a 1.5% discount
• OR pay as little as 10% and take up to 2 months to pay off the balance, interest free
• No annual membership fee for the first year—a savings of $185
• A powerful cash flow management tool
APPLY NOW |
 
- Organic food producers ask FDA to mandate labeling of biotech foods
Advocates and producers of organic foods sent a legal petition to the FDA asking for mandatory labeling of biotech foods in order to avoid misleading consumers and prevent economic fraud. They also unveiled a website that could serve as a venue for consumers to post their comments in support of the cause. A spokeswoman for the FDA said that the petition hasn't officially reached the agency and that foods from biotech plants "must meet the same safety and legal standards as foods derived from their non-genetically engineered counterparts." Google/Agence France-Presse (10/4)  | LET’S GO DESIGN: Episode #5
In this episode of SolidWorks’ interactive web series, Jeremy moves closer to the final design of our Hot Rod Baby Buggy and also hot-wires the golf cart motor to show how the aluminum tracks perform flawlessly. Watch at LetsGoDesign.tv. |
 | News from BIO | | | | - Join the leaders of the biotech industry in Shanghai
At BIO China, Oct. 12 and 13, you'll have unprecedented opportunities to meet the leaders of China's most innovative biotech companies, many of whom have not attended conferences outside of China. Hear from speakers and panelists with insights into regulatory issues, intellectual property, clinical trials, manufacturing and product distribution in China. The conference also will feature one-on-one partnering meetings, company presentations, networking opportunities and an exhibit hall. Register now.
| SmartQuote | | | |  | The direct use of force is such a poor solution to any problem, it is generally employed only by small children and large nations."
--David Friedman,
American economist and writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, October 04, 2011
- Monday, October 03, 2011
- Friday, September 30, 2011
- Thursday, September 29, 2011
- Wednesday, September 28, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment